Peptide evidence, examined across women's lives

Were women included? Were outcomes analyzed by sex?

Source-linked coverage of what peptide-medicine research does—and does not—show for women across life stages. Every claim traces back to an FDA label, trial registry, or peer-reviewed record.

Search medicines, trials, topics Explore all audits

Featured audit

R1S3

SURMOUNT-1 (NCT04184622) and the broader SURMOUNT program

Women / female participants

0.0%

of 0 enrolled

Women were enrolled in large numbers in the tirzepatide obesity development program, but interpretable sex-specific analyses and life-stage denominators remain limited.

Read the full audit

1 / 4

Medicines profiled

Representation audits

Life-stage hubs

Source-linked explainers

Where in a woman's life?

Evidence changes across life stages

Click any stage to see what the research does—and does not—cover for that period. We keep pregnancy, lactation, and reproductive-potential evidence explicitly separate; a label that applies to one does not apply to the others.

Life stage

Reproductive years

Open the hub

From menarche through the premenopausal adult years, including menstrual-cycle variation and contraception considerations.

Current evidence gaps

Contraceptive interaction data
Menstrual-cycle effects

Medicine profiles

What the evidence shows for each medicine

All medicines

Tirzepatide

Dual GIP/GLP-1 receptor agonist

Brand: Mounjaro, Zepbound

Women included; analysis limitedPregnancy/lactation data limited

Semaglutide

GLP-1 receptor agonist

Brand: Ozempic, Wegovy

Sex analysis reportedPregnancy/lactation data limited

Kisspeptin

Reproductive neuropeptide pathway modulator

Preclinical onlyLife-stage evidence limited

Leuprolide

GnRH agonist

Brand: Lupron

Women-specific evidencePregnancy/lactation data limited

Degarelix

GnRH antagonist

Brand: Firmagon

No reliable evidence foundPregnancy/lactation data limited

Teriparatide

Parathyroid hormone analog (peptide fragment)

Brand: Forteo, Bonsity

Women-specific evidencePregnancy/lactation data limited

What we still do not know

Open questions in women's peptide research

These are unresolved evidence gaps we track. Tap any card to see why it matters.

Recent explainers

Source-linked reading

Learn library

Peptide medicines and women's health

How to read evidence about peptide therapies across women's lives.

Reading sex subgroup results

Why a significant p-value in one subgroup does not prove a sex difference.

Pregnancy and lactation labels

How to find and interpret reproductive-risk language in FDA labels.

How we grade women-specific evidence

Two grades. Reported separately. Never combined into a single score.

Representation (R1–R4)

Who was enrolled, in what numbers, and with what life-stage detail. Grades the participant pool, not the results.

Sex analysis (S1–S5)

Whether outcomes were analyzed by sex, prespecified, and adequately powered. Grades the analytic method, not the trial.

Traceable sources

Every material claim links to the FDA label, ClinicalTrials.gov record, or peer-reviewed publication it comes from.

Read the full methodology

Weekly, source-linked

The Women's Evidence Brief

One representation audit, one study update, and one practical evidence-literacy lesson each week. We never ask about your health.

Join the waitlist

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.